Rigel Therapeutics has expanded its oncology portfolio with REZLIDHIA and GAVRETO, alongside its original molecule TAVALISSE for chronic immune thrombocytopenia. The company’s IRAK1/4 inhibitor ...

This performance was largely driven by the impressive growth of REZLIDHIA, the company’s mIDH1 inhibitor for relapsed/refractory acute myeloid leukemia (AML), which saw a 107% year-over-year ...

After hours: March 13 at 5:07:52 PM EDT Loading Chart for RIGL ...

This performance was largely driven by the impressive growth of REZLIDHIA, the company’s mIDH1 inhibitor for relapsed/refractory acute myeloid leukemia (AML), which saw a 107% year-over-year increase.

Rigel制药公司成立于1996年，总部位于南旧金山，专注于开发血液系统疾病和癌症治疗方案。根据 InvestingPro 的财务数据显示，该公司保持着2.13的健康流动比率，每股收益达到$0.99。公司股票在过去六个月上涨近60%。投资者可以通过 InvestingPro 独家提供的综合研究报告，深入了解Rigel的财务健康状况和增长前景，该报告涵盖超过1,400家美国股票的详细分析和可操作情报 ...

Revenue for the fourth quarter was $57.6 million, with product revenues from Tavalisse, Rezlidhia, and Gavreto contributing significantly. Citi analysts have raised their price target for Rigel to ...